Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.
about
Maternal exposure to ambient levels of benzene and neural tube defects among offspring: Texas, 1999-2004Role of oxidative stress in female reproductionRegulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in TransplantationLocalized fetomaternal hyperglycemia: spatial and kinetic definition by positron emission tomographyThalidomide-induced teratogenesis: history and mechanismsThe Roles of Glutathione Peroxidases during Embryo DevelopmentAir toxics and birth defects: a Bayesian hierarchical approach to evaluate multiple pollutants and spina bifidaExpression of base excision, mismatch, and recombination repair genes in the organogenesis-stage rat conceptus and effects of exposure to a genotoxic teratogen, 4-hydroperoxycyclophosphamideSelective leukemic-cell killing by a novel functional class of thalidomide analogsNitrones as therapeutics.Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Immunomodulatory drugs in myelodysplastic syndromes.Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.Thalidomide-a notorious sedative to a wonder anticancer drug.Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cellsAngiogenesis inhibitors: current strategies and future prospects.Pathogenesis of diabetes-induced congenital malformations.Thalidomide: the tragedy of birth defects and the effective treatment of disease.Prevention of fetal malformation with antioxidants in diabetic pregnancy.Embryo toxicity and teratogenicity of formaldehyde.Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells.Teratogenic effects of thalidomide: molecular mechanisms.Thalidomide: an old drug with new clinical applications.Thalidomide and its derivatives: emerging from the wilderness.Apoptosis and transplantation tolerance.Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease.Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells.The balance of deletion and regulation in allograft tolerance.T-cell costimulatory pathways in allograft rejection and tolerance.Clinical trials: where are we now?Embryo stability and vulnerability in an always changing world.The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsThalidomide for the treatment of multiple myeloma.Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Thalidomide: present and future in multiple myeloma.
P2860
Q23919549-E002FE35-181E-4729-A311-93792EF067BEQ24814956-04735693-2299-4163-A3B7-6A2B0F2C3785Q26784460-095B2E1A-9D95-45A6-9023-9C7C6F6EF8FCQ27321833-8BDBC85A-DBF0-4A43-9000-71205B84BCA8Q28085087-31D5FA14-359A-41F4-8BDC-D36814E910FCQ28390835-68AC2CA9-E564-44D7-B1AB-860296631BF6Q28393920-6F48FF78-0912-4A3C-BEAB-7446CF0BECEFQ28569407-CA210203-E329-42B5-89DA-8A75EB72A9EBQ30479632-2BA90A1A-50A3-4264-BD92-D5701AB8CF21Q30484564-286BB6BF-08AF-45BD-91D3-E240CE929944Q30830907-2B7295F4-29FA-4B55-8F12-8D1889507A31Q33364235-D994DB98-440F-4EC5-A9AB-89947B8E9E26Q33371622-265A6E43-CB92-46DB-8D11-16567DC8869EQ33382047-ED387EA8-E5CB-44AD-A71B-B03BB9869F8BQ33948719-6D42D829-395B-4F8A-B593-82E9A1B6024BQ33956871-638101C9-4FA4-476D-8169-5D01C67EB6DAQ33986673-F3EC976D-9E23-4E63-9F81-8DE024D03014Q34056376-6FE53E59-3BB8-482C-9BD1-C93770436012Q34091873-7CF75149-0353-4DD2-9AD1-A226D7C17438Q34179690-AE1D1819-F0A5-4623-849B-CAF295B5D1DFQ34268964-37DE1157-4927-4B88-8DD1-4765C314B83CQ34381463-CC04BA9C-0F85-4700-B9FA-5553B5FE063FQ34406463-F02CB8BA-4042-4982-9679-BC1F8CD352DBQ34660391-60FDD97B-D0C6-4C3B-A82E-ECBE0A379FBCQ34798767-FF5A61F7-5D3F-4A41-9126-6E362FC12C91Q35107977-6393EC05-977A-421B-BBEC-30A35F660BE4Q35129735-B85B6BD1-9BE8-47C7-8BE8-AB3DFA923A75Q35198923-AFECB5EA-7ABA-49AD-BFC0-3246CAF7F207Q35198927-756ABFB7-F342-4BAD-95B4-730B1BE95436Q35216089-CF3B6E50-B9E1-4D50-90BC-8817568BE9F3Q35583506-548BC7E4-219D-4C99-9D20-AEF235E7FC57Q35583511-A09E0E3D-EA8E-4451-9F51-EFF2E8F78F2FQ35583542-4BCE0EF5-0E0D-46E4-AF28-971896ADA0DFQ35629412-552121A1-CC1B-4B40-8C5E-D7533CCCD234Q35828711-0E6526FA-F403-47EA-955F-708C11DAD408Q35870500-43E0BFC7-F3B8-4590-A948-D3002B821638Q36012329-EACDB3C6-BF4A-4F9D-B8ED-7ED77DB77540Q36059602-7AA7EE28-3E9A-47F5-B50C-8D7E32C09F13Q36061821-4D1DF6F5-D3F2-41FB-97B7-C8D2F5AEFE33Q36066131-5C34F872-561D-45F4-8A34-845D3F0678E4
P2860
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@en
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@nl
type
label
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@en
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@nl
prefLabel
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@en
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@nl
P2093
P921
P356
P1433
P1476
Free radical-mediated oxidativ ...... of thalidomide teratogenicity.
@en
P2093
P2888
P304
P356
10.1038/8466
P407
P577
1999-05-01T00:00:00Z